Madrigal Pharma (MDGL) Misses Q4 EPS by 44c

Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($5.68), $0.44 worse than the analyst estimate of ($5.24).

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs